Future research should focus on developing selective HDAC10 inhibitors and exploring their synergistic effects with existing chemotherapeutic agents to enhance treatment efficacy and overcome resistance in CTCL. Here, HDAC10 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.